International Journal of Radiation Oncology * Biology * Physics
Volume 69, Issue 4 , Pages 1238-1245 , 15 November 2007

Assessment of Tumor Response to the Vascular Disrupting Agents 5,6-Dimethylxanthenone-4-Acetic Acid or Combretastatin-A4-Phosphate by Intrinsic Susceptibility Magnetic Resonance Imaging

  • Lesley D. McPhail, Ph.D.

      Affiliations

    • CRUK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    • Department of Basic Medical Sciences, St. George's, University of London, London, United Kingdom
    • Corresponding Author InformationReprint requests to: Lesley D. McPhail, Ph.D., Institute of Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG, United Kingdom. Tel: (+44) (0) 20-8661-3738; Fax: (+44) (0) 20-8661-0846
    • ,
  • John R. Griffiths, D.Phil.

      Affiliations

    • Department of Basic Medical Sciences, St. George's, University of London, London, United Kingdom
    • ,
  • Simon P. Robinson, Ph.D.

      Affiliations

    • CRUK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    • Department of Basic Medical Sciences, St. George's, University of London, London, United Kingdom

Received 21 June 2007 ,Revised 15 August 2007 ,Accepted 16 August 2007.

References 

  1. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture. Cancer Res. 1986;46:147–173
  2. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res. 1989;49:6449–6465
  3. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–257
  4. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer. 2004;100:2491–2499
  5. Siemann DW, Bibby MC, Dark GG, et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res. 2005;11:416–420
  6. Kelland LR. Targeting established tumor vasculature: A novel approach to cancer treatment. Curr Cancer Ther Rev. 2005;1:1–9
  7. Tozer GM, Kanthou C, Baguley BC. Disrupting tumor blood vessels. Nat Rev Cancer. 2005;5:423–435
  8. Michaelis LC, Ratain MJ. Measuring response in a post-RECIST world: From black and white to shades of grey. Nat Rev Cancer. 2006;6:409–414
  9. Galbraith SM, Rustin GJ, Lodge MA, et al. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging. J Clin Oncol. 2002;20:3826–3840
  10. Maxwell RJ, Wilson J, Prise VE, et al. Evaluation of the anti-vascular effects of combretastatin in rodent tumors by dynamic contrast enhanced MRI. NMR Biomed. 2002;15:89–98
  11. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002;62:3408–3416
  12. Robinson SP, McIntyre DJ, Checkley D, et al. Tumor dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer. 2003;88:1592–1597
  13. Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol. 2003;21:4428–4438
  14. Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol. 2003;21:2831–2842
  15. Evelhoch JL, LoRusso PM, He Z, et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res. 2004;10:3650–3657
  16. McPhail LM, McIntyre DJO, Ludwig C, et al. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. Neoplasia. 2006;8:199–206
  17. Padhani AR, Choyke PL. New techniques in oncologic imaging. New York: Taylor and Francis; 2006;p. 257–269
  18. Robinson SP, Kalber TL, Howe FA, et al. Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging. Neoplasia. 2005;7:466–474
  19. Blakey DC, Westwood FR, Walker M, et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res. 2002;8:1974–1983
  20. Galbraith SM, Chaplin DJ, Lee F, et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumor vascular targeting activity in vivo. Anticancer Res. 2001;21:93–102
  21. Workman P, Twentyman P, Balkwill F, et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer. 1998;77:1–10
  22. Howe FA, Robinson SP, Rodrigues LM, et al. Flow and oxygenation dependent (FLOOD) contrast MR imaging to monitor the response of rat tumors to carbogen breathing. Magn Reson Imaging. 1999;17:1307–1318
  23. Robinson SP, Rodrigues LM, Howe FA, et al. Effects of different levels of hypercapnic hyperoxia on tumor R2∗ and arterial blood gases. Magn Reson Imaging. 2001;19:161–166
  24. Denekamp J, Hill SA, Hobson B. Vascular occlusion and tumor cell death. Eur J Cancer Clin Oncol. 1983;19:271–275
  25. Leach MO, Brindle KM, Evelhoch JL, et al. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: Issues and recommendations. Br J Cancer. 2005;92:1599–1610
  26. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging. 1999;10:223–232
  27. McKeage M, Fong P, Jeffery M, et al. 5,6-dimethyxanthenone-4-acetic acid in the treatment of refactory tumors: A phase I safety study of a vascular disrupting agent. Clin Cancer Res. 2006;12:1776–1784
  28. O'Connor JPB, Jackson A, Parker GJM, et al. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer. 2007;96:189–195
  29. Murata R, Overgaard J, Horsman MR. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumor and normal tissues. Int J Radiat Biol. 2001;77:195–204
  30. Tozer GM, Prise VE, Wilson J, et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res. 1999;59:1626–1634
  31. Ferrero E, Villa A, Ferrero ME, et al. Tumor necrosis factor alpha-induced vascular leakage involves PECAM1 phosphorylation. Cancer Res. 1996;56:3211–3215
  32. Hofmann S, Grasberger H, Jung P, et al. The tumor necrosis factor-alpha induced vascular permeability is associated with a reduction of VE-cadherin expression. Eur J Med Res. 2002;7:171–176
  33. Lejeune FJ. Clinical use of TNF revisited: Improving penetration of anti-cancer agents by increasing vascular permeability. J Clin Invest. 2002;110:433–435
  34. Nwariaku FE, Chang J, Zhu X, et al. The role of p38 map kinase in tumor necrosis factor-induced redistribution of vascular endothelial cadherin and increased endothelial permeability. Shock. 2002;18:82–85
  35. Kerkar S, Williams M, Blocksom J, et al. TNF-alpha and IL-1beta increase pericyte/endothelial cell co-culture permeability. J Surg Res. 2006;132:40–45
  36. Griffiths JR, Taylor NJ, Howe FA, et al. The response of human tumors to carbogen breathing, monitored by gradient-recalled echo magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 1997;39:697–701
  37. Padhani AR. MRI for evaluating antivascular cancer treatments. Br J Radiol. 2003;76:S60–S80

 J. R. Griffith's present address is CRUK Cambridge Research Institute, Robinson Way, Cambridge CB2 0RE, United Kingdom.

 Supported by Cancer Research UK, Grant CI 6412/A6269 and The Royal Society. S.P.R. is the recipient of a Royal Society University Research Fellowship.

 Conflict of interest: none.

PII: S0360-3016(07)03910-7

doi: 10.1016/j.ijrobp.2007.08.025

International Journal of Radiation Oncology * Biology * Physics
Volume 69, Issue 4 , Pages 1238-1245 , 15 November 2007

Article Tools

* Image Usage & Resolution